| Brinzolamide nanocrystal formulations for ophthalmic delivery: reduction of elevated intraocular pressure in vivo A Tuomela, P Liu, J Puranen, S Rönkkö, T Laaksonen, G Kalesnykas, ... International journal of pharmaceutics 467 (1-2), 34-41, 2014 | 124 | 2014 |
| Retinal degeneration in a mouse model of CLN5 disease is associated with compromised autophagy H Leinonen, V Keksa-Goldsteine, S Ragauskas, P Kohlmann, Y Singh, ... Scientific reports 7 (1), 1597, 2017 | 63 | 2017 |
| Early retinal function deficit without prominent morphological changes in the R6/2 mouse model of Huntington’s disease S Ragauskas, H Leinonen, J Puranen, S Rönkkö, S Nymark, K Gurevicius, ... PLoS One 9 (12), e113317, 2014 | 45 | 2014 |
| Topical ocular pharmacokinetics and bioavailability for a cocktail of atenolol, timolol and betaxolol in rabbits A Fayyaz, VP Ranta, E Toropainen, KS Vellonen, A Valtari, J Puranen, ... European Journal of Pharmaceutical Sciences 155, 105553, 2020 | 22 | 2020 |
| Liposomal sunitinib for ocular drug delivery: A potential treatment for choroidal neovascularization S Tavakoli, J Puranen, S Bahrpeyma, VE Lautala, S Karumo, T Lajunen, ... International Journal of Pharmaceutics 620, 121725, 2022 | 19 | 2022 |
| Ocular pharmacokinetics of atenolol, timolol and betaxolol cocktail: Tissue exposures in the rabbit eye A Fayyaz, KS Vellonen, VP Ranta, E Toropainen, M Reinisalo, A Valtari, ... European Journal of Pharmaceutics and Biopharmaceutics 166, 155-162, 2021 | 19 | 2021 |
| Ocular metabolism and distribution of drugs in the rabbit eye: Quantitative assessment after intracameral and intravitreal administrations EM Del Amo, A Hammid, M Tausch, E Toropainen, A Sadeghi, A Valtari, ... International Journal of Pharmaceutics 613, 121361, 2022 | 16 | 2022 |
| Pharmacokinetics of pullulan–dexamethasone conjugates in retinal drug delivery E Kicková, A Sadeghi, J Puranen, S Tavakoli, M Sen, VP Ranta, ... Pharmaceutics 14 (1), 12, 2021 | 14 | 2021 |
| Imaging, quantitation and kinetic modelling of intravitreal nanomaterials A Sadeghi, M Ruponen, J Puranen, S Cao, R Ridolfo, S Tavakoli, ... International Journal of Pharmaceutics 621, 121800, 2022 | 13 | 2022 |
| Pharmacokinetics of intravitreal macromolecules: Scaling between rats and rabbits A Sadeghi, J Puranen, M Ruponen, A Valtari, A Subrizi, VP Ranta, ... European Journal of Pharmaceutical Sciences 159, 105720, 2021 | 12 | 2021 |
| Retinal neuroprotection by controlled release of a VCP inhibitor from self-assembled nanoparticles M Sen, M Al-Amin, E Kicková, A Sadeghi, J Puranen, A Urtti, P Caliceti, ... Journal of Controlled Release 339, 307-320, 2021 | 11 | 2021 |
| Magnetically assisted drug delivery of topical eye drops maintains retinal function in vivo in mice M Bassetto, D Ajoy, F Poulhes, C Obringer, A Walter, N Messadeq, ... Pharmaceutics 13 (10), 1650, 2021 | 6 | 2021 |
| Antiangiogenic AAV2 gene therapy with a truncated form of soluble VEGFR-2 reduces the growth of choroidal neovascularization in mice after intravitreal injection J Puranen, S Koponen, T Nieminen, I Kanerva, E Kokki, P Toivanen, ... Experimental Eye Research 224, 109237, 2022 | 5 | 2022 |
| Neuroprotective effects of mas-receptor ligands in an experimental rat glaucoma A Vaajanen, J Puranen, G Kalesnykas, H Vapaatalo, H Uusitalo J Pharm Pharmacol 2, 114-122, 2014 | 1 | 2014 |
